Detecting immune inflammation and brain changes in schizophrenia
Official title: Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in Schizophrenia
Run by Central South University · NCT06673966 · Data updated 2026-11-12
This study looks at how inflammation in the immune system might be linked to schizophrenia by comparing patients with the condition to healthy individuals over three months.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Central South University Academic / other |
| Locations | 1 site (Changsha, Hunan) |
| Status | Recruiting |
| Started | January 10, 2025 |
| Main results expected | February 1, 2027 |
| Study ends | December 31, 2028 |
| Registry record updated | July 17, 2026 |
| Trial ID | NCT06673966 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with schizophrenia according to ICD-11 criteria.
✕Probably not a fit
Patients with neurodevelopmental disorders, bipolar disorder, or severe physical illnesses may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the relationship between immune-inflammatory states and schizophrenia by analyzing clinical, biological, and imaging data. It involves a cohort of patients diagnosed with schizophrenia who will be followed for three months, during which various assessments will be conducted, including clinical evaluations and biological sample collection. The study also includes a control group of healthy individuals matched for age and sex to provide comparative data. The goal is to identify potential subtypes of schizophrenia based on immune responses and their correlation with treatment outcomes and cognitive function.
Why it matters
Potential benefit: If successful, this study could lead to improved classification and treatment strategies for schizophrenia based on immune-inflammatory profiles.
How similar studies have gone: Previous studies have indicated a potential link between immune responses and schizophrenia, suggesting that this approach may yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Clinical diagnosis that meets ICD-11 criteria for schizophrenia. 2. Confirmation of the diagnosis of schizophrenia using the SCID-5-RV. Exclusion Criteria: 1. Clinical diagnosis or SCID-5-RV assessment confirming neurodevelopmental disorders, bipolar and related disorders, substance use disorders (excluding alcohol and tobacco). 2. Presence of severe or acute physical illnesses, including traumatic brain injury, intracranial space-occupying or infectious diseases, acute cardiovascular diseases, acute respiratory system diseases, acute hematological disorders, autoimmune disease, etc. 3. Presence of clearly defined genetic diseases, including tuberous sclerosis, multiple sclerosis, Kleefstra syndrome, 22q11.2 deletion syndrome, Prader-Willi syndrome, Klinefelter syndrome (47, XXY), etc.
Where it's running
-
Department of Psychiatry, the Second Xiangya Hospital of Central South University
Changsha, Hunan, China Recruiting
Study contacts
- Study coordinator: Renrong Wu, M.D., Ph.D.
- Email: wurenrong2013@163.com
- Phone: +86 15874179855
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding early psychosis and its biological markers
This study is trying to find out more about early signs of psychotic disorders like schizophrenia and bipolar disorder by looking at brain scans and other health data from around 320 participants over a year.
-
Using Lumateperone to improve motivation in patients with schizophrenia and psychosis
This study is testing if Lumateperone can help people with schizophrenia or schizoaffective disorders feel more motivated and less apathetic.
-
Education on sexual dysfunction for patients with schizophrenia and diabetes
This study tests whether providing education about sexual dysfunction can help adults with schizophrenia and diabetes feel better about their sexual health while they are on antipsychotic medication.
-
Examining the effects of combined therapy for schizophrenia
This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.
-
XEP527 in stable schizophrenia: safety and how it behaves in the body
This small, early-stage study tests the safety and how XEP527 behaves in people with stable schizophrenia who are on a single antipsychotic.
-
Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations
This study tests whether theta-burst transcranial magnetic stimulation can lessen persistent auditory verbal hallucinations in adults with schizophrenia-spectrum or psychotic disorders who have not responded to antipsychotic meds.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.